AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26711904 — intervention group
Group type: EXPERIMENTAL
Intervention: Empower Resilience Intervention
Number of subjects: 0
Study 26711904 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23735727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin treatment
Number of subjects: 24
Study 23735727 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 24
Study 21815827 — intervention group
Group type: EXPERIMENTAL
Intervention: KCit + Splenda
Number of subjects: 12
Study 21815827 — intervention group
Group type: COMPARATOR
Intervention: KCit
Number of subjects: 12
Study 18482937 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 476
Study 18482937 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G benzathine
Number of subjects: 476
Study 18482937 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 476
Study 15677701 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 200
Study 15677701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12183309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions for urinary tract infections
Number of subjects: 120
Study 12183309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions for sore throat
Number of subjects: 120
Study 12183309 — intervention group
Group type: COMPARATOR
Intervention: Control group for urinary tract infections
Number of subjects: 120
Study 12183309 — intervention group
Group type: COMPARATOR
Intervention: Control group for sore throat
Number of subjects: 120
Study 10213440 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 1
Study 7753950 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit memory tasks with varying associative set sizes and word frequencies
Number of subjects: 0
Study 2191993 — intervention group
Group type: EXPERIMENTAL
Intervention: L-648,051 (inhaled cysteinyl leukotriene antagonist)
Number of subjects: 10
Study 2191993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 125 mg/10 kg
Number of subjects: 60
Study 6782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 250 mg/10 kg
Number of subjects: 60
Study 6782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.4 mg/10 kg
Number of subjects: 60
Study 6782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.8 mg/10 kg
Number of subjects: 60
Study 6782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 250 mg/10 kg and Oxycodone 0.8 mg/10 kg
Number of subjects: 60
Study 6782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 60
Study 6782930 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 60
Study 31198138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy (HFNC) with initial flow rate of 40 L/min
Number of subjects: 74
Study 31198138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy (HFNC)
Number of subjects: 74
Study 31198138 — intervention group
Group type: COMPARATOR
Intervention: Routine oxygen therapy
Number of subjects: 74
Study 28348504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 ml, 8 mg) with bupivacaine (18 ml, 0.5%)
Number of subjects: 44
Study 28348504 — intervention group
Group type: COMPARATOR
Intervention: Control (2 ml normal saline with bupivacaine (18 ml, 0.5%))
Number of subjects: 44
Study 24642392 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological antioxidant potential (BAP) levels measured at 6 months
Number of subjects: 69
Study 24642392 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased 6-month BAP level
Number of subjects: 69
Study 22310838 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week posturography-assisted vestibular rehabilitation protocol and home-based exercise program (Group A)
Number of subjects: 30
Study 22310838 — intervention group
Group type: COMPARATOR
Intervention: Awaiting spontaneous compensation (Group B)
Number of subjects: 30
Study 21502546 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone, consisting of goserelin and bicalutamide for 2 years
Number of subjects: 983
Study 19467753 — intervention group
Group type: EXPERIMENTAL
Intervention: Crew Resource Management (CRM) training
Number of subjects: 29
Study 19467753 — intervention group
Group type: COMPARATOR
Intervention: Classic simulator training (MED)
Number of subjects: 29
Study 19467753 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CRM and MED)
Number of subjects: 29
Study 16671435 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (4 patients with plateau waves)
Number of subjects: 8
Study 16671435 — intervention group
Group type: COMPARATOR
Intervention: Group B (4 intracranial hypertensive, hypoperfused patients)
Number of subjects: 8
Study 16671435 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 8
Study 16671435 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 8
Study 15857212 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002 40 mg/day
Number of subjects: 59
Study 15857212 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002 100 mg/day
Number of subjects: 59
Study 15857212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12149758 — intervention group
Group type: COMPARATOR
Intervention: Traditional anesthetic (thiopental, pancuronium, 50 microg/kg fentanyl)
Number of subjects: 80
Study 12149758 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track anesthetic (propofol, cisatracurium, 20 microg/kg fentanyl)
Number of subjects: 80
Study 10643535 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy with mitozantrone and methotrexate (2M) +/‐ mitomycin‐C (3M) and tamoxifen, used concurrently with radiation
Number of subjects: 184
Study 7790432 — intervention group
Group type: EXPERIMENTAL
Intervention: New immunodiagnostic method of complement fixation
Number of subjects: 0
Study 2112120 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy in 1 fraction
Number of subjects: 37
Study 2112120 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy in 5 fractions
Number of subjects: 37
Study 373632 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate
Number of subjects: 12
Study 373632 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine maleate
Number of subjects: 12
Study 373632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31623638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training (36 sessions)
Number of subjects: 54
Study 27866873 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label tenofovir (300 mg daily) for 1 year
Number of subjects: 1315
Study 26556601 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 41
Study 26556601 — intervention group
Group type: COMPARATOR
Intervention: Physical modality (SIT)
Number of subjects: 41
Study 23665299 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on reading food labels to choose low sodium products (single session)
Number of subjects: 78
Study 23665299 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control group)
Number of subjects: 78
Study 21917824 — intervention group
Group type: EXPERIMENTAL
Intervention: SC abatacept (125 mg)
Number of subjects: 167
Study 21917824 — intervention group
Group type: COMPARATOR
Intervention: SC placebo
Number of subjects: 167
Study 21917824 — intervention group
Group type: EXPERIMENTAL
Intervention: SC abatacept (125 mg) reintroduced after placebo
Number of subjects: 167
Study 19444379 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage containing 200 mg calcium and 5 microg vitamin D daily for 30 days
Number of subjects: 64
Study 19444379 — intervention group
Group type: COMPARATOR
Intervention: Beverage containing 200 mg calcium daily for 30 days
Number of subjects: 64
Study 17535285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and aluminium lactate-containing toothpaste (test group)
Number of subjects: 59
Study 17535285 — intervention group
Group type: COMPARATOR
Intervention: Minus active control toothpaste (control group)
Number of subjects: 59
Study 15582922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 20
Study 15582922 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 20
Study 11169032 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux ultrafiltrates (UFs)
Number of subjects: 0
Study 11169032 — intervention group
Group type: COMPARATOR
Intervention: Low-flux ultrafiltrates (UFs)
Number of subjects: 0
Study 9504950 — intervention group
Group type: EXPERIMENTAL
Intervention: Total osteocalcin (tOC)
Number of subjects: 257
Study 9504950 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercarboxylated osteocalcin (ucOC)
Number of subjects: 257
Study 9504950 — intervention group
Group type: COMPARATOR
Intervention: Subjects with hip fracture
Number of subjects: 257
Study 8048341 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 54
Study 8048341 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 54
Study 8048341 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 54
Study 2737797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal
Number of subjects: 6
Study 2737797 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 6
Study 31335305 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity for Lent (PAL) program
Number of subjects: 128
Study 30477276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest serum 25(OH)D quartile (4.7–17.5 ng/mL)
Number of subjects: 271
Study 30477276 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum 25(OH)D quartile
Number of subjects: 271
Study 30477276 — intervention group
Group type: EXPERIMENTAL
Intervention: Second serum 25(OH)D quartile
Number of subjects: 271
Study 27863599 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxation
Number of subjects: 150
Study 27863599 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group
Number of subjects: 150
Study 27863599 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 25103953 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glycemic dysregulation
Number of subjects: 75
Study 25103953 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically revised patients
Number of subjects: 75
Study 22197127 — intervention group
Group type: EXPERIMENTAL
Intervention: degarelix-ML group
Number of subjects: 85
Study 22197127 — intervention group
Group type: COMPARATOR
Intervention: placebo group
Number of subjects: 85
Study 22197127 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 85
Study 20525274 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab followed by Palivizumab (M/P)
Number of subjects: 260
Study 20525274 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab followed by Motavizumab (P/M)
Number of subjects: 260
Study 20525274 — intervention group
Group type: COMPARATOR
Intervention: Motavizumab only (control)
Number of subjects: 260
Study 20525274 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 260
Study 17906021 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate
Number of subjects: 348
Study 17906021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 16141775 — intervention group
Group type: EXPERIMENTAL
Intervention: HEARTFELT intervention
Number of subjects: 0
Study 16141775 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated historical control)
Number of subjects: 0
Study 12441212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature
Number of subjects: 333
Study 12441212 — intervention group
Group type: COMPARATOR
Intervention: Barometric pressure
Number of subjects: 333
Study 9935007 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-sotalol
Number of subjects: 146
Study 9935007 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic medication (ICD-only group)
Number of subjects: 146
Study 7591508 — intervention group
Group type: EXPERIMENTAL
Intervention: High hypnotizability (10-12 SHSSC)
Number of subjects: 33
Study 7591508 — intervention group
Group type: COMPARATOR
Intervention: Low hypnotizability (0-4 SHSSC)
Number of subjects: 33
Study 7591508 — intervention group
Group type: EXPERIMENTAL
Intervention: High hypnotizability (10-12 SHSSC) with angry emotional valence presented to the right hemisphere (LVF)
Number of subjects: 33
Study 7591508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with higher absorption and sustained attention
Number of subjects: 33
Study 2267970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg) administered monthly for 12 months
Number of subjects: 0
Study 2267970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg) administered monthly for 8 and 12 months
Number of subjects: 0
Study 2267970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg) administered monthly
Number of subjects: 0
Study 2267970 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 0
Study 6104874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed betablocker diuretic combination (Torrat, Boehringer Mannheim GmbH)
Number of subjects: 66
Study 6104874 — intervention group
Group type: COMPARATOR
Intervention: Single components (metipranolol and butizide)
Number of subjects: 66
Study 31783279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885
Study 31783279 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885
Study 31783279 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding events
Number of subjects: 13885
Study 31798894 — intervention group
Group type: EXPERIMENTAL
Intervention: Boot Camp intervention (diabetes education and medication management via initial clinic and weekly virtual visits for 90 days)
Number of subjects: 366
Study 31798894 — intervention group
Group type: EXPERIMENTAL
Intervention: Boot Camp intervention
Number of subjects: 366
Study 31798894 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes care management (control group)
Number of subjects: 366
Study 29989320 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphorical restructuring
Number of subjects: 88
Study 29989320 — intervention group
Group type: COMPARATOR
Intervention: Literal restructuring
Number of subjects: 88
Study 29989320 — intervention group
Group type: COMPARATOR
Intervention: No restructuring
Number of subjects: 88
Study 27590218 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg per day (reduced to 30 mg if certain factors present)
Number of subjects: 2199
Study 27590218 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin-warfarin
Number of subjects: 2199
Study 27590218 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199
Study 24604308 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 50 mg daily for 24 months
Number of subjects: 30
Study 24604308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22313516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 50 or 100 mg
Number of subjects: 60
Study 22313516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20841613 — intervention group
Group type: COMPARATOR
Intervention: 10 units of lispro
Number of subjects: 7
Study 20841613 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 units of lispro
Number of subjects: 7
Study 20841613 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 units of lispro
Number of subjects: 7
Study 17602978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H)
Number of subjects: 678
Study 17602978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study 15617963 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral symmetrical stair‐case technique
Number of subjects: 48
Study 15617963 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral method using two asymmetrical flaps
Number of subjects: 48
Study 15617963 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral flap
Number of subjects: 48
Study 15617963 — intervention group
Group type: EXPERIMENTAL
Intervention: Bernard‐Freeman‐Fries technique
Number of subjects: 48
Study 12374520 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate, 1500 mg once a day
Number of subjects: 202
Study 12374520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 12374520 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 202
Study 10815855 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser‐generated 308‐nm UV‐B radiation (1 treatment at 8 and 16 MED multiples)
Number of subjects: 13
Study 10815855 — intervention group
Group type: COMPARATOR
Intervention: Excimer laser‐generated 308‐nm UV‐B radiation (low and medium fluences)
Number of subjects: 13
Study 10815855 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser‐generated 308‐nm UV‐B radiation (high fluences)
Number of subjects: 13
Study 8984537 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem + vancomycin (arm A)
Number of subjects: 126
Study 8984537 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem + teicoplanin (arm B)
Number of subjects: 126
Study 8984537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential empiric therapy including amikacin and amphotericin B
Number of subjects: 126
Study 8984537 — intervention group
Group type: COMPARATOR
Intervention: Overall group
Number of subjects: 126
Study 1455126 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Tendency group
Number of subjects: 15
Study 1455126 — intervention group
Group type: COMPARATOR
Intervention: Non-Morning Tendency group
Number of subjects: 15
Study 1455126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 3881032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 162
Study 3881032 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% levobunolol
Number of subjects: 162
Study 3881032 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 162
Study 3881032 — intervention group
Group type: COMPARATOR
Intervention: levobunolol vs timolol
Number of subjects: 162
Study 30299241 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ+MTX
Number of subjects: 165
Study 30299241 — intervention group
Group type: COMPARATOR
Intervention: TCZ+PBO
Number of subjects: 165
Study 29448265 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini dental implants (MDI)
Number of subjects: 42
Study 29448265 — intervention group
Group type: COMPARATOR
Intervention: Standard-size implants (SSI)
Number of subjects: 42
Study 27209300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound at time 0
Number of subjects: 20
Study 27209300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound at 60 minutes
Number of subjects: 20
Study 27209300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound at 90 minutes
Number of subjects: 20
Study 24570078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine continuous infusion (0.5 µg/kg per min)
Number of subjects: 50
Study 24570078 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 50
Study 22435910 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based TRM intervention
Number of subjects: 8
Study 22435910 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 8
Study 20357309 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive-behavioural therapy (CCBT)
Number of subjects: 0
Study 20357309 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 20357309 — intervention group
Group type: COMPARATOR
Intervention: CCBT plus TAU
Number of subjects: 0
Study 18418966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongguan Capsule (TGC)
Number of subjects: 100
Study 18418966 — intervention group
Group type: COMPARATOR
Intervention: Western routine therapy with anti-thrombosis and anti-coagulant agents
Number of subjects: 100
Study 16186280 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg vitamin C and 100 IU vitamin E (group V)
Number of subjects: 69
Study 16186280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of magnesium plus zinc, vitamins C plus E (group MV)
Number of subjects: 69
Study 16186280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 69
Study 16186280 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Mg and 30 mg Zn (group M)
Number of subjects: 69
Study 12639462 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM (cell culture medium supplemented with insulin, thyroxin and growth hormone)
Number of subjects: 48
Study 12639462 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM
Number of subjects: 48
Study 12639462 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 48
Study 11018196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg IR
Number of subjects: 123
Study 11018196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg ER
Number of subjects: 123
Study 11018196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 160 mg ER
Number of subjects: 123
Study 11018196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin ER (all doses)
Number of subjects: 123
Study 8639252 — intervention group
Group type: COMPARATOR
Intervention: CyA (7 mg/kg per day) and prednisolone
Number of subjects: 147
Study 8639252 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA (7 mg/kg per day), prednisolone, and oral nifedipine
Number of subjects: 147